Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...

HONG KONG -- U.S. President Donald Trump's latest threat to impose steep blanket tariffs on a range of imports that includes drugs underscores another key friction point in the economic rivalry ...

There are three possible outcomes if a needle somehow traveled at a speed of more than 670 million mph and hit our planet If a needle for whatever reason was in space heading on a crash course for ...

Many people get a "pins and needles" sensation from time to time, and the tingling feeling can sometimes leave us wanting to curl up into a ball until it goes away. This annoying feeling normally ...

This zone typically resides about 5,000 feet above the surface. Close up of snow needles on car (KXAN photo/Todd Bailey) Snow needles seen in Austin (Courtesy Gregory Phillips) Snow needles appear ...

(MENAFN- GlobeNewsWire - Nasdaq) If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for Dupixent to treat adults with bullous pemphigoid.